世界の成人悪性神経膠腫治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Adult Malignant Glioma Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0113 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、成人悪性神経膠腫治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（多形性膠芽腫、退形成性星状細胞腫、退形成性乏突起膠腫、その他）、用途別市場規模（病院、専門クリニック、がん・放射線治療センター、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・成人悪性神経膠腫治療の市場動向 ・企業の競争状況、市場シェア ・成人悪性神経膠腫治療の種類別市場規模（多形性膠芽腫、退形成性星状細胞腫、退形成性乏突起膠腫、その他） ・成人悪性神経膠腫治療の用途別市場規模（病院、専門クリニック、がん・放射線治療センター、その他） ・成人悪性神経膠腫治療の北米市場規模2016-2027（アメリカ、カナダ） ・成人悪性神経膠腫治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・成人悪性神経膠腫治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・成人悪性神経膠腫治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・成人悪性神経膠腫治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Merck、Hoffmann-La Roche、Arbor Pharmaceuticals、Pfizer、AbbVie、Amgen、Bristol-Myers Squibb、Sun Pharmaceutical、Teva Pharmaceutical、Novocure、Eli Lilly、AstraZeneca、Novartis AG） ・結論

Glioma is a broad category of brain and spinal cord tumors that come from glial cells brain cells that support nerve cells.The symptoms, prognosis, and treatment of a glioma depend on the person’s age, the exact type of tumor, and the location of the tumor within the brain.

Market Analysis and Insights: Global Adult Malignant Glioma Therapeutics Market
The global Adult Malignant Glioma Therapeutics market size is projected to reach US$ 1807.4 million by 2026, from US$ 1261 million in 2019, at a CAGR of 5.2% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Adult Malignant Glioma Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Adult Malignant Glioma Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Adult Malignant Glioma Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Adult Malignant Glioma Therapeutics market.

Global Adult Malignant Glioma Therapeutics Scope and Market Size
Adult Malignant Glioma Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Adult Malignant Glioma Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Other

Segment by Application
Hospitals
Specialty Clinics
Cancer and Radiation Therapy Centers
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Merck
Hoffmann-La Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceutical
Teva Pharmaceutical
Pfizer
AbbVie

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adult Malignant Glioma Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Glioblastoma Multiforme
1.2.3 Anaplastic Astrocytoma
1.2.4 Anaplastic Oligodendroglioma
1.2.5 Other
1.3 Market by Application
1.3.1 Global Adult Malignant Glioma Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Cancer and Radiation Therapy Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Adult Malignant Glioma Therapeutics Market Perspective (2016-2027)
2.2 Adult Malignant Glioma Therapeutics Growth Trends by Regions
2.2.1 Adult Malignant Glioma Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Adult Malignant Glioma Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Adult Malignant Glioma Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Adult Malignant Glioma Therapeutics Industry Dynamic
2.3.1 Adult Malignant Glioma Therapeutics Market Trends
2.3.2 Adult Malignant Glioma Therapeutics Market Drivers
2.3.3 Adult Malignant Glioma Therapeutics Market Challenges
2.3.4 Adult Malignant Glioma Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Adult Malignant Glioma Therapeutics Players by Revenue
3.1.1 Global Top Adult Malignant Glioma Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Adult Malignant Glioma Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Adult Malignant Glioma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Adult Malignant Glioma Therapeutics Revenue
3.4 Global Adult Malignant Glioma Therapeutics Market Concentration Ratio
3.4.1 Global Adult Malignant Glioma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adult Malignant Glioma Therapeutics Revenue in 2020
3.5 Adult Malignant Glioma Therapeutics Key Players Head office and Area Served
3.6 Key Players Adult Malignant Glioma Therapeutics Product Solution and Service
3.7 Date of Enter into Adult Malignant Glioma Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Adult Malignant Glioma Therapeutics Breakdown Data by Type
4.1 Global Adult Malignant Glioma Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Type (2022-2027)

5 Adult Malignant Glioma Therapeutics Breakdown Data by Application
5.1 Global Adult Malignant Glioma Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Adult Malignant Glioma Therapeutics Market Size (2016-2027)
6.2 North America Adult Malignant Glioma Therapeutics Market Size by Type
6.2.1 North America Adult Malignant Glioma Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Adult Malignant Glioma Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Adult Malignant Glioma Therapeutics Market Size by Type (2016-2027)
6.3 North America Adult Malignant Glioma Therapeutics Market Size by Application
6.3.1 North America Adult Malignant Glioma Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Adult Malignant Glioma Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Adult Malignant Glioma Therapeutics Market Size by Application (2016-2027)
6.4 North America Adult Malignant Glioma Therapeutics Market Size by Country
6.4.1 North America Adult Malignant Glioma Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Adult Malignant Glioma Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Adult Malignant Glioma Therapeutics Market Size (2016-2027)
7.2 Europe Adult Malignant Glioma Therapeutics Market Size by Type
7.2.1 Europe Adult Malignant Glioma Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Adult Malignant Glioma Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Adult Malignant Glioma Therapeutics Market Size by Type (2016-2027)
7.3 Europe Adult Malignant Glioma Therapeutics Market Size by Application
7.3.1 Europe Adult Malignant Glioma Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Adult Malignant Glioma Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Adult Malignant Glioma Therapeutics Market Size by Application (2016-2027)
7.4 Europe Adult Malignant Glioma Therapeutics Market Size by Country
7.4.1 Europe Adult Malignant Glioma Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Adult Malignant Glioma Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Type
8.2.1 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Application
8.3.1 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Region
8.4.1 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Adult Malignant Glioma Therapeutics Market Size (2016-2027)
9.2 Latin America Adult Malignant Glioma Therapeutics Market Size by Type
9.2.1 Latin America Adult Malignant Glioma Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Adult Malignant Glioma Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Adult Malignant Glioma Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Adult Malignant Glioma Therapeutics Market Size by Application
9.3.1 Latin America Adult Malignant Glioma Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Adult Malignant Glioma Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Adult Malignant Glioma Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Adult Malignant Glioma Therapeutics Market Size by Country
9.4.1 Latin America Adult Malignant Glioma Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Adult Malignant Glioma Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Type
10.2.1 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Application
10.3.1 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Country
10.4.1 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Adult Malignant Glioma Therapeutics Introduction
11.1.4 Merck Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.1.5 Merck Recent Development
11.2 Hoffmann-La Roche
11.2.1 Hoffmann-La Roche Company Details
11.2.2 Hoffmann-La Roche Business Overview
11.2.3 Hoffmann-La Roche Adult Malignant Glioma Therapeutics Introduction
11.2.4 Hoffmann-La Roche Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.2.5 Hoffmann-La Roche Recent Development
11.3 Arbor Pharmaceuticals
11.3.1 Arbor Pharmaceuticals Company Details
11.3.2 Arbor Pharmaceuticals Business Overview
11.3.3 Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Introduction
11.3.4 Arbor Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.3.5 Arbor Pharmaceuticals Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Adult Malignant Glioma Therapeutics Introduction
11.4.4 Pfizer Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 AbbVie
11.5.1 AbbVie Company Details
11.5.2 AbbVie Business Overview
11.5.3 AbbVie Adult Malignant Glioma Therapeutics Introduction
11.5.4 AbbVie Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.5.5 AbbVie Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Adult Malignant Glioma Therapeutics Introduction
11.6.4 Amgen Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.6.5 Amgen Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Company Details
11.7.2 Bristol-Myers Squibb Business Overview
11.7.3 Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Introduction
11.7.4 Bristol-Myers Squibb Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Sun Pharmaceutical
11.8.1 Sun Pharmaceutical Company Details
11.8.2 Sun Pharmaceutical Business Overview
11.8.3 Sun Pharmaceutical Adult Malignant Glioma Therapeutics Introduction
11.8.4 Sun Pharmaceutical Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.8.5 Sun Pharmaceutical Recent Development
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Company Details
11.9.2 Teva Pharmaceutical Business Overview
11.9.3 Teva Pharmaceutical Adult Malignant Glioma Therapeutics Introduction
11.9.4 Teva Pharmaceutical Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.9.5 Teva Pharmaceutical Recent Development
11.10 Novocure
11.10.1 Novocure Company Details
11.10.2 Novocure Business Overview
11.10.3 Novocure Adult Malignant Glioma Therapeutics Introduction
11.10.4 Novocure Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.10.5 Novocure Recent Development
11.11 Eli Lilly
11.11.1 Eli Lilly Company Details
11.11.2 Eli Lilly Business Overview
11.11.3 Eli Lilly Adult Malignant Glioma Therapeutics Introduction
11.11.4 Eli Lilly Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.11.5 Eli Lilly Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Details
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Adult Malignant Glioma Therapeutics Introduction
11.12.4 AstraZeneca Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.12.5 AstraZeneca Recent Development
11.13 Novartis AG
11.13.1 Novartis AG Company Details
11.13.2 Novartis AG Business Overview
11.13.3 Novartis AG Adult Malignant Glioma Therapeutics Introduction
11.13.4 Novartis AG Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021)
11.13.5 Novartis AG Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Adult Malignant Glioma Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Glioblastoma Multiforme
Table 3. Key Players of Anaplastic Astrocytoma
Table 4. Key Players of Anaplastic Oligodendroglioma
Table 5. Key Players of Other
Table 6. Global Adult Malignant Glioma Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Adult Malignant Glioma Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Adult Malignant Glioma Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Adult Malignant Glioma Therapeutics Market Share by Regions (2016-2021)
Table 10. Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Adult Malignant Glioma Therapeutics Market Share by Regions (2022-2027)
Table 12. Adult Malignant Glioma Therapeutics Market Trends
Table 13. Adult Malignant Glioma Therapeutics Market Drivers
Table 14. Adult Malignant Glioma Therapeutics Market Challenges
Table 15. Adult Malignant Glioma Therapeutics Market Restraints
Table 16. Global Adult Malignant Glioma Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Adult Malignant Glioma Therapeutics Market Share by Players (2016-2021)
Table 18. Global Top Adult Malignant Glioma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adult Malignant Glioma Therapeutics as of 2020)
Table 19. Ranking of Global Top Adult Malignant Glioma Therapeutics Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Adult Malignant Glioma Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Adult Malignant Glioma Therapeutics Product Solution and Service
Table 23. Date of Enter into Adult Malignant Glioma Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Adult Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Adult Malignant Glioma Therapeutics Revenue Market Share by Type (2016-2021)
Table 27. Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Adult Malignant Glioma Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Adult Malignant Glioma Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Adult Malignant Glioma Therapeutics Revenue Market Share by Application (2016-2021)
Table 31. Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Adult Malignant Glioma Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Adult Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Adult Malignant Glioma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Adult Malignant Glioma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Adult Malignant Glioma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Adult Malignant Glioma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Adult Malignant Glioma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Adult Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Adult Malignant Glioma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Adult Malignant Glioma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Adult Malignant Glioma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Adult Malignant Glioma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Adult Malignant Glioma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Adult Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Adult Malignant Glioma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Adult Malignant Glioma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Adult Malignant Glioma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Adult Malignant Glioma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Adult Malignant Glioma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 63. Merck Company Details
Table 64. Merck Business Overview
Table 65. Merck Adult Malignant Glioma Therapeutics Product
Table 66. Merck Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 67. Merck Recent Development
Table 68. Hoffmann-La Roche Company Details
Table 69. Hoffmann-La Roche Business Overview
Table 70. Hoffmann-La Roche Adult Malignant Glioma Therapeutics Product
Table 71. Hoffmann-La Roche Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 72. Hoffmann-La Roche Recent Development
Table 73. Arbor Pharmaceuticals Company Details
Table 74. Arbor Pharmaceuticals Business Overview
Table 75. Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Product
Table 76. Arbor Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 77. Arbor Pharmaceuticals Recent Development
Table 78. Pfizer Company Details
Table 79. Pfizer Business Overview
Table 80. Pfizer Adult Malignant Glioma Therapeutics Product
Table 81. Pfizer Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 82. Pfizer Recent Development
Table 83. AbbVie Company Details
Table 84. AbbVie Business Overview
Table 85. AbbVie Adult Malignant Glioma Therapeutics Product
Table 86. AbbVie Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 87. AbbVie Recent Development
Table 88. Amgen Company Details
Table 89. Amgen Business Overview
Table 90. Amgen Adult Malignant Glioma Therapeutics Product
Table 91. Amgen Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 92. Amgen Recent Development
Table 93. Bristol-Myers Squibb Company Details
Table 94. Bristol-Myers Squibb Business Overview
Table 95. Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Product
Table 96. Bristol-Myers Squibb Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 97. Bristol-Myers Squibb Recent Development
Table 98. Sun Pharmaceutical Company Details
Table 99. Sun Pharmaceutical Business Overview
Table 100. Sun Pharmaceutical Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 101. Sun Pharmaceutical Recent Development
Table 102. Teva Pharmaceutical Company Details
Table 103. Teva Pharmaceutical Business Overview
Table 104. Teva Pharmaceutical Adult Malignant Glioma Therapeutics Product
Table 105. Teva Pharmaceutical Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 106. Teva Pharmaceutical Recent Development
Table 107. Novocure Company Details
Table 108. Novocure Business Overview
Table 109. Novocure Adult Malignant Glioma Therapeutics Product
Table 110. Novocure Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 111. Novocure Recent Development
Table 112. Eli Lilly Company Details
Table 113. Eli Lilly Business Overview
Table 114. Eli Lilly Adult Malignant Glioma Therapeutics Product
Table 115. Eli Lilly Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 116. Eli Lilly Recent Development
Table 117. AstraZeneca Company Details
Table 118. AstraZeneca Business Overview
Table 119. AstraZeneca Adult Malignant Glioma Therapeutics Product
Table 120. AstraZeneca Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 121. AstraZeneca Recent Development
Table 122. Novartis AG Company Details
Table 123. Novartis AG Business Overview
Table 124. Novartis AG Adult Malignant Glioma Therapeutics Product
Table 125. Novartis AG Revenue in Adult Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 126. Novartis AG Recent Development
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Adult Malignant Glioma Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Glioblastoma Multiforme Features
Figure 3. Anaplastic Astrocytoma Features
Figure 4. Anaplastic Oligodendroglioma Features
Figure 5. Other Features
Figure 6. Global Adult Malignant Glioma Therapeutics Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Specialty Clinics Case Studies
Figure 9. Cancer and Radiation Therapy Centers Case Studies
Figure 10. Others Case Studies
Figure 11. Adult Malignant Glioma Therapeutics Report Years Considered
Figure 12. Global Adult Malignant Glioma Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Adult Malignant Glioma Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Adult Malignant Glioma Therapeutics Market Share by Regions: 2020 VS 2027
Figure 15. Global Adult Malignant Glioma Therapeutics Market Share by Regions (2022-2027)
Figure 16. Global Adult Malignant Glioma Therapeutics Market Share by Players in 2020
Figure 17. Global Top Adult Malignant Glioma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adult Malignant Glioma Therapeutics as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Adult Malignant Glioma Therapeutics Revenue in 2020
Figure 19. Global Adult Malignant Glioma Therapeutics Revenue Market Share by Type (2016-2021)
Figure 20. Global Adult Malignant Glioma Therapeutics Revenue Market Share by Type (2022-2027)
Figure 21. North America Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Adult Malignant Glioma Therapeutics Market Share by Type (2016-2027)
Figure 23. North America Adult Malignant Glioma Therapeutics Market Share by Application (2016-2027)
Figure 24. North America Adult Malignant Glioma Therapeutics Market Share by Country (2016-2027)
Figure 25. United States Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Adult Malignant Glioma Therapeutics Market Share by Type (2016-2027)
Figure 29. Europe Adult Malignant Glioma Therapeutics Market Share by Application (2016-2027)
Figure 30. Europe Adult Malignant Glioma Therapeutics Market Share by Country (2016-2027)
Figure 31. Germany Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Adult Malignant Glioma Therapeutics Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Adult Malignant Glioma Therapeutics Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Adult Malignant Glioma Therapeutics Market Share by Region (2016-2027)
Figure 41. China Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Adult Malignant Glioma Therapeutics Market Share by Type (2016-2027)
Figure 49. Latin America Adult Malignant Glioma Therapeutics Market Share by Application (2016-2027)
Figure 50. Latin America Adult Malignant Glioma Therapeutics Market Share by Country (2016-2027)
Figure 51. Mexico Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Adult Malignant Glioma Therapeutics Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Adult Malignant Glioma Therapeutics Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Adult Malignant Glioma Therapeutics Market Share by Country (2016-2027)
Figure 57. Turkey Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Adult Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Merck Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 61. Hoffmann-La Roche Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 62. Arbor Pharmaceuticals Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 63. Pfizer Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 64. AbbVie Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 65. Amgen Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 66. Bristol-Myers Squibb Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 67. Sun Pharmaceutical Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 68. Teva Pharmaceutical Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 69. Novocure Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 70. Eli Lilly Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 71. AstraZeneca Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 72. Novartis AG Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

---